Akeso Inc.
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Other Names/Subsidiaries
- Akesobio
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology
Latest on Akeso Inc.
Bristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
Summit Therapeutics and Akeso delivered mixed results from the first multi-regional Phase III study of ivonescimab, the companies’ PD-1/VEGF-targeting immunotherapy, in non-small cell lung cancer (NSC
Pfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it
The US Food and Drug Administration’s missed user fee goal date for Stealth BioTherapeutics ’ Barth syndrome drug elamipretide may be another signal of drug regulatory work slowed by recent layoffs a